Cargando…
Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression
Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application. Tumor...
Autores principales: | Shi, Linlin, Sheng, Jianyong, Wang, Mengli, Luo, Han, Zhu, Jun, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592171/ https://www.ncbi.nlm.nih.gov/pubmed/31281535 http://dx.doi.org/10.7150/thno.35131 |
Ejemplares similares
-
Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance
por: Shi, Linlin, et al.
Publicado: (2020) -
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020) -
Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013) -
TGFβ: Signaling Blockade for Cancer Immunotherapy
por: Chen, Szu-Ying, et al.
Publicado: (2022) -
Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells
por: Wang, Tingting, et al.
Publicado: (2019)